Stock comparison
AxoGen
Harmony Biosciences Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AXGN
AxoGen
Market cap
$2.17B
Sector
Healthcare
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AXGN | HRMY | Winner |
|---|---|---|---|
| Warren Buffett | 19F | 67B | HRMY |
| Benjamin Graham | 54D | 60C | HRMY |
| Philip Fisher | 40D | 75B | HRMY |
| Peter Lynch | 27F | 62C | HRMY |
| Joel Greenblatt | 0F | 28F | HRMY |
| Charlie Munger | 26F | 62C | HRMY |
| Terry Smith | 27F | 67B | HRMY |
Side-by-side metrics
| Metric | AXGN | HRMY |
|---|---|---|
| Market cap | $2.17B | $1.75B |
| P/E (TTM) | - | 11.8x |
| EV/EBIT | - | 6.4x |
| ROIC (TTM) | -3.4% | 12.5% |
| Gross margin | 75.01% | 76.55% |
| Net margin | -13.21% | 16.2% |
| Revenue CAGR 5y | 15.32% | 29.85% |
| EPS CAGR 5y | - | 46.45% |
| Debt / Equity | 0.1x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AXGN leads on
- P/E (TTM)-vs 11.8x+117%
- EV/EBIT-vs 6.4x+102%
- Debt / Equity0.1xvs 0.2x+63%
- Market cap$2.17Bvs $1.75B+20%
HRMY leads on
- Net margin16.2%vs -13.21%+182%
- ROIC (TTM)12.5%vs -3.4%+127%
- Revenue CAGR 5y29.85%vs 15.32%+49%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.